Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Novo Holdings A/S

Q3 2023 · 13F-HR

Novo Holdings A/Sholdings as filed

Filed 2023-11-14 · accession 0000950123-23-010600

$1.35B
Reported value
40
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
11271J107BNBROOKFIELD CORP$121.3M8.97%3,880,230CommonSOLE
N07059210ASMLASML HOLDING N V$116.4M8.60%197,760CommonSOLE
79466L302CRMSALESFORCE.COM, INC.$107.6M7.95%530,500CommonSOLE
218352102CORTCORCEPT THERAPEUTICS INC$92.0M6.80%3,377,768CommonSOLE
51655R101LANZATECH GLOBAL INC$73.9M5.46%15,814,845CommonSOLE
12685J105CABOCABLE ONE INC$72.9M5.39%118,403CommonSOLE
874039100TSMTAIWAN SEMICONDUCTOR MFG LTD$61.8M4.56%710,780CommonSOLE
254604101IRONDISC MEDICINE, INC.$51.2M3.79%1,090,772CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$47.4M3.50%1,500,000CommonSOLE
01609W102BABAALIBABA GROUP HLDG LTD$43.4M3.21%500,827CommonSOLE
92243G108PCVXVAXCYTE INC$43.1M3.18%845,000CommonSOLE
03940C100ACLXGBXARCELLX, INC.$38.6M2.85%1,075,000CommonSOLE
037833100AAPLAPPLE INC$37.9M2.80%221,460CommonSOLE
09061G101BMRNBIOMARIN PHARMACEUTICAL INC$35.4M2.62%400,000CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$34.8M2.57%6,071,703CommonSOLE
81181C104SEAGEN INC.$33.9M2.51%159,986CommonSOLE
457669307INSMINSMED INC$33.8M2.50%1,339,304CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$32.7M2.42%1,100,000CommonSOLE
N69605108PHVSPHARVARIS N V$27.7M2.05%1,329,325CommonSOLE
09627Y1092655787DBLUEPRINT MEDICINES CORP$26.4M1.95%525,000CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$25.5M1.88%2,095,900CommonSOLE
75974E103RENEO PHARMACEUTICALS INC$25.3M1.87%3,330,377CommonSOLE
23257D103CBAYUSDCYMABAY THERAPEUTICS INC$23.4M1.73%1,566,521CommonSOLE
02043Q107ALNYALNYLAM PHARMACEUTICALS INC$21.0M1.55%118,383CommonSOLE
113004105BAMBROOKFIELD ASSET MANAGMT LTD$20.9M1.55%627,207CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$20.5M1.52%1,001,000CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$15.3M1.13%1,200,000CommonSOLE
85209E109SPRUCE BIOSCIENCES INC$15.2M1.12%6,722,336CommonSOLE
457730109INSPINSPIRE MED SYS INC$11.9M0.88%60,000CommonSOLE
449778109IOBTQIO BIOTECH INC$8.1M0.60%5,747,067CommonSOLE
75120L100RALLYBIO CORP$7.4M0.54%2,187,999CommonSOLE
00288U106ABCLABCELLERA BIOLOGICS INC$5.2M0.38%1,126,915CommonSOLE
82710M100SILKUSDSILK RD MED INC$5.0M0.37%333,884CommonSOLE
89455T109TMCITREACE MED CONCEPTS INC$4.7M0.35%360,000CommonSOLE
N515171054PKBLAVA THERAPEUTICS NV$3.5M0.26%2,400,000CommonSOLE
57142B104MQMARQETA INC$2.6M0.20%441,558CommonSOLE
23284P103CYTEIR THERAPEUTICS INC$1.9M0.14%676,379CommonSOLE
36322Q107GLTOUSDGALECTO INC$1.8M0.13%2,497,791CommonSOLE
49705R105KNTEUSDKINNATE BIOPHARMA INC$1.1M0.08%815,707CommonSOLE
84833T103SPROSPERO THERAPEUTICS INC$567,3710.04%468,902CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.